ORPHA:263479
Fuchs heterochromic iridocyclitis
Also known as: FHI
Publications
608
80.4th percentile
Trials
0
Interventional, condition-specific
Researchers
947
Distinct authors in sample
Gene link
—
Readiness
1/6
Stages with a signal
Clinical definition (Orphanet)
Fuchs heterochromic iridocyclitis (FHI) is an ocular disease of unknown occurring in a very small percentage (0.5-6.2%) of uveitis cases, characterized by diffuse iris heterochromia or atrophy, keratic precipitates in the absence of synechiae, and in some cases evolving to glaucoma and vitreous opacities.
How rare: 1-9 / 1 000 000 — roughly one to nine people per million. In a city the size of Kolkata, perhaps a few dozen.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0016989
- UMLS:C0016782
Additional Mondo synonyms (4)
Fuchs heterochromic cyclitis · Fuchs heterochromic uveitis · Fuchs' heterochromic cyclitis · Fuchs' heterochromic uveitis
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
1/6 stages with a signal
Research-stage checklist from open sources (GenCC, literature, Monarch when enriched, ClinicalTrials.gov). Not a prognosis or care recommendation.
- Gene identifiedNot found
No GenCC disease–gene assertion in this build
- LiteraturePresent
608 matched papers (224 in last 10 years) Source
- Phenotype characterisedNot checked
Not yet enriched from Monarch / HPO
- Animal modelNot checked
Not yet enriched from Monarch / Alliance
- Orphan designationNot checked
FDA/EMA orphan-drug designation not enriched yet
- Interventional trialNot found
No matched interventional trial under our ClinicalTrials.gov rules
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Not yet — the cause hasn't been pinned down in GenCC.
No strong gene–disease assertion joined for this Orphanet entity.
Phenotypes (Monarch / HPO)
Not enriched in this build — Monarch phenotype joins were not run for this record.
Animal models (Monarch / Alliance)
Not enriched in this build.
Literature
Is anyone studying this?
608
608 papers have been published on this condition. That is a real research literature — still far smaller than common diseases (breast cancer: over 700,000 papers). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=5449) is 41.
608 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 41 (publications denominator n=5449).
224 in the last 10 years · medium confidence · 80.4th percentile (publications denominator)
Phrase hits: 608 · MeSH hits: 0
Who's working on it?
947
Distinct author names in 200 sampled papers — named people below.
Who's working on it?
No interventional trial matched this name; these authors publish on it in the sampled literature — a practical starting point for contact.
- 01Rothova A9 papers · 2023
Department of Ophthalmology, Erasmus Medical Center, Erasmus University, Rotterdam, the Netherlands.
Papers in Europe PMC - 02de-la-Torre A5 papers · 2025
NeURos research group, Escuela de Medicina y Ciencias de la salud, Universidad del Rosario, Carrera 24 # 63 C 69, Bogotá, Colombia. alejadelatorre@yahoo.com.
Papers in Europe PMC - 03Kianersi F5 papers · 2025
Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran.
Papers in Europe PMC - 04
- 05Bhargava R4 papers · 2024
From the Departments of *Ophthalmology and †Pathology, School of Medical Sciences and Research, Sharda University, Greater Noida; and ‡Department of Ophthalmology, Rotary Eye Hospital, Maranda, Palampur, India.
Papers in Europe PMC - 06Bodaghi B4 papers · 2024
Department of Ophthalmology, Hôpital de la Pitié-Salpêtrière, Paris, France.
Papers in Europe PMC - 07Hassanpour K4 papers · 2024
Ophthalmic Research Center, Shahid Beheshti University of Medical Sciences, Tehran, Tehran, 19839-63113, Iran.
Papers in Europe PMC - 08Pourazizi M4 papers · 2025
Isfahan Eye Research Center, Department of Ophthalmology, Isfahan University of Medical Sciences, Isfahan, Iran.
Papers in Europe PMC - 09Acharya NR3 papers · 2026
Francis I. Proctor Foundation, University of California San Francisco, San Francisco, CA, USA; Department of Ophthalmology, University of California, San Francisco, CA, USA.
Papers in Europe PMC - 10
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present).
Data as of 27 July 2026
No matched interventional trials. This is true for 73% of diseases in the trials denominator (5114 of 7003). Here are the researchers publishing on it.
medium confidence · 36.5th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
See who's working on it — people publishing on this disease are often the practical next contact when no trial is listed.
Where to find support
We do not yet link condition-specific patient organisations. These umbrella groups support undiagnosed and ultra-rare families:
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
"Fuchs heterochromic iridocyclitis" OR "Fuchs heterochromic cyclitis" OR "Fuchs heterochromic uveitis" OR "Fuchs' heterochromic cyclitis" OR "Fuchs' heterochromic uveitis"
ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"Fuchs heterochromic iridocyclitis" OR "Fuchs heterochromic cyclitis" OR "Fuchs heterochromic uveitis" OR "Fuchs' heterochromic cyclitis" OR "Fuchs' heterochromic uveitis"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Query health: ok — strategies attempted: phrase; with hits: phrase
Run this search on ClinicalTrials.gov
Synonyms dropped by stoplist: FHI
Confidence reasoning
- Preferred label is multi-word and distinctive
- 1 synonym(s) dropped by stoplist (may under-count)
- No label/synonym collisions with other diseases in this corpus
Ingested 2026-07-27T11:22:17.614Z